Tumour necrosis factor-α as a tumour promoter

European Journal of Cancer

Volumn 42, Issue 6, 2006, Pages 745-750

  Szlosarek, Peter ^a   Charles, Kellie A ^a   Balkwill, Frances R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cancer; TNF

Indexed keywords

ADENOVIRUS VECTOR; BACTERIAL TOXIN; CYTOKINE; CYTOTOXIC AGENT; I KAPPA B; PACLITAXEL; SMALL INTERFERING RNA; THALIDOMIDE; TNFERADE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR PROMOTER; UNCLASSIFIED DRUG;

ARTICLE; CACHEXIA; CANCER; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CARCINOGENESIS; CARCINOMA; CELL COMMUNICATION; CHRONIC INFLAMMATION; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG FEVER; DRUG MEGADOSE; EXPOSURE; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULE; NONHUMAN; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SARCOMA; SERRATIA MARCESCENS; SERUM; STREPTOCOCCUS PYOGENES; STROMA CELL; TISSUE LEVEL; TUMOR CELL; TUMOR NECROSIS; TUMOR PROMOTION; VIRAL GENE THERAPY;

ANIMALS; CHRONIC DISEASE; HUMANS; INFLAMMATION; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; NECROSIS; NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646472252     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.01.012     Document Type: Article

References (72)

1. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
2. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
3. Balkwill F., Charles K.A., and Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 (2005) 211-217
4. Tlsty T.D. Stromal cells can contribute oncogenic signals. Semin Cancer Biol 11 (2001) 97-104
5. van Kempen L.C., Ruiter D.J., van Muijen G.N., and Coussens L.M. The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol 82 (2003) 539-548
6. Aggarwal B.B., Samanta A., and Feldmann M. In: Oppenheim J., and Feldmann M. (Eds). TNF-α cytokine reference vol. 1 (2000), Academic Press, London 413-433
7. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
8. Locksley R.M., Killeen N., and Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104 (2001) 487-501
9. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., and Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72 (1975) 3666-3670
10. MacEwan D.J. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 14 (2002) 477-492
11. Chen G., and Goeddel D.V. TNF-R1 signaling: a beautiful pathway. Science 296 (2002) 1634-1635
12. Micheau O., and Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114 (2003) 181-190
13. Wajant H., Pfizenmaier K., and Scheurich P. Tumor necrosis factor signalling. Cell Death Differ 10 (2003) 45-65
14. Szlosarek P.W., and Balkwill F.R. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 4 (2003) 565-573
15. Noach L.A., Bosma N.B., Jansen J., Hoek F.J., van Deventer S.J., and Tytgat G.N. Mucosal tumor necrosis factor-α, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 29 (1994) 425-429
16. Noguchi M., Hiwatashi N., Liu Z., and Toyota T. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut 43 (1998) 203-209
17. Szlosarek PW, Grimshaw MJ, Kulbe H, et al. Expression and regulation of tumor necrosis factor-α in normal and malignant ovarian epithelium. Mol Cancer Ther 2006 (in press).
18. Tselepis C., Perry I., Dawson C., et al. Tumour necrosis factor-αin Barrett's oesophagus: a potential novel mechanism of action. Oncogene 21 (2002) 6071-6081
19. Nauts H.C., Fowler G.A., and Bogatko F.H. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumours in man. Acta Medica Scandinavia 145 (1953) S276
20. Ruegg C., Yilmaz A., Bieler G., Bamat J., Chaubert P., and Lejeune F.J. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4 (1998) 408-414
21. Havell E.A., Fiers W., and North R.J. The anti-tumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med 167 (1988) 1067-1085
22. Asher A., Mule J.J., Reichert C.M., Shiloni E., and Rosenberg S.A. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138 (1987) 963-974
23. Lee R.K., Spielman J., Zhao D.Y., Olsen K.J., and Podack E.R. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J Immunol 157 (1996) 1919-1925
24. Ratner A., and Clark W.R. Role of TNF-α in CD8+ cytotoxic T lymphocyte-mediated lysis. J Immunol 150 (1993) 4303-4314
25. Baxevanis C.N., and Papamichail M. Characterization of the anti-tumor immune response in human cancers and strategies for immunotherapy. Crit Rev Oncol Hematol 16 (1994) 157-179
26. Jiang H., Stewart C.A., Fast D.J., and Leu R.W. Tumor target-derived soluble factor synergizes with IFN-gamma and IL-2 to activate macrophages for tumor necrosis factor and nitric oxide production to mediate cytotoxicity of the same target. J Immunol 149 (1992) 2137-2146
27. Zganiacz A., Santosuosso M., Wang J., et al. TNF-αis a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J Clin Invest 113 (2004) 401-413
28. Mundt A.J., Vijayakumar S., Nemunaitis J., et al. A phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res 10 (2004) 5747-5753
29. Gaiotti D., Chung J., Iglesias M., et al. Tumor necrosis factor-α promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway. Mol Carcinog 27 (2000) 97-109
30. Wu S., Boyer C.M., Whitaker R.S., et al. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 53 (1993) 1939-1944
31. Maeda M., Watanabe N., Okamoto T., et al. Endogenous tumor necrosis factor functions as a resistant factor against adriamycin. Int J Cancer 58 (1994) 376-379
32. Mizokami A., Gotoh A., Yamada H., et al. Tumor necrosis factor-αrepresses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol 164 (2000) 800-805
33. Jaiswal M., LaRusso N.F., Burgart L.J., et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 60 (2000) 184-190
34. Murakami A., Kawabata K., Koshiba T., et al. Nitric oxide synthase is induced in tumor promoter-sensitive, but not tumor promoter-resistant, JB6 mouse epidermal cells cocultured with interferon-gamma-stimulated RAW264.7 cells: the role of tumor necrosis factor-α. Cancer Res 60 (2000) 6326-6331
35. Weichselbaum R.R., Kufe D.W., Hellman S., et al. Radiation-induced tumour necrosis factor-α expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol 3 (2002) 665-671
36. Leibovich S.J., Polverini P.J., Shepard H.M., et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α. Nature 329 (1987) 630-632
37. Bussolino F., Camussi G., and Baglioni C. Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha. J Biol Chem 263 (1988) 11856-11861
38. Cheng N., and Chen J. Tumor necrosis factor-α induction of endothelial ephrin A1 expression is mediated by a p38 MAPK- and SAPK/JNK-dependent but nuclear factor-kappa B-independent mechanism. J Biol Chem 276 (2001) 13771-13777
39. De Cesaris P., Starace D., Starace G., et al. Activation of Jun N-terminal kinase/stress-activated protein kinase pathway by tumor necrosis factor alpha leads to intercellular adhesion molecule-1 expression. J Biol Chem 274 (1999) 28978-28982
40. Leek R.D., Landers R., Fox S.B., et al. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 77 (1998) 2246-2251
41. Yoshida S., Ono M., Shono T., et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17 (1997) 4015-4023
42. Battegay E.J., Raines E.W., Colbert T., et al. TNF-α stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression. J Immunol 154 (1995) 6040-6047
43. Leber T.M., and Balkwill F.R. Regulation of monocyte MMP-9 production by TNF-α and a tumour-derived soluble factor (MMPSF). Br J Cancer 78 (1998) 724-732
44. Rosen E.M., Goldberg I.D., Liu D., et al. Tumor necrosis factor stimulates epithelial tumor cell motility. Cancer Res 51 (1991) 5315-5321
45. Hagemann T., Wilson J., Kulbe H., et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 175 (2005) 1197-1205
46. Kulbe H., Hagemann T., Szlosarek P.W., et al. The inflammatory cytokine tumor necrosis factor-α regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 65 (2005) 10355-10362
47. Bates R.C., and Mercurio A.M. Tumor necrosis factor-α stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell 14 (2003) 1790-1800 Epub 2003 Jan 26
48. Moore R.J., Owens D.M., Stamp G., et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nat Med 5 (1999) 828-831
49. Suganuma M., Okabe S., Marino M.W., et al. Essential role of tumor necrosis factor alpha (TNF-α) in tumor promotion as revealed by TNF-α-deficient mice. Cancer Res 59 (1999) 4516-4518
50. Arnott C.H., Scott K.A., Moore R.J., et al. Tumour necrosis factor-α mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway. Oncogene 21 (2002) 4728-4738
51. Arnott C.H., Scott K.A., Moore R.J., Robinson S.C., Thompson R.G., and Balkwill F.R. Expression of both TNF-α receptor subtypes is essential for optimal skin tumour development. Oncogene 23 (2004) 1902-1910
52. Roberts R.A., and Kimber I. Cytokines in non-genotoxic hepatocarcinogenesis. Carcinogenesis 20 (1999) 1397-1401
53. Knight B., Yeoh G.C., Husk K.L., et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 192 (2000) 1809-1818
54. Kitakata H., Nemoto-Sasaki Y., Takahashi Y., et al. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res 62 (2002) 6682-6687
55. Ueno Y., Sakurai H., Matsuo M., Choo M.K., Koizumi K., and Saiki I. Selective inhibition of TNF-α-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib. Br J Cancer 92 (2005) 1690-1695
56. Korner H., Cretney E., Wilhelm P., et al. Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype. J Exp Med 191 (2000) 89-96
57. Orosz P., Echtenacher B., Falk W., et al. Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med 177 (1993) 1391-1398
58. Malik S.T., Naylor M.S., East N., et al. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer 26 (1990) 1031-1034
59. Qin Z., Kruger-Krasagakes S., Kunzendorf U., et al. Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis. J Exp Med 178 (1993) 355-360
60. Waterston A.M., Salway F., Andreakos E., Butler D.M., Feldmann M., and Coombes R.C. TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model. Br J Cancer 90 (2004) 1279-1284
61. Komori A., Yatsunami J., Suganuma M., et al. Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. Cancer Res 53 (1993) 1982-1985
62. Malik S.T., Griffin D.B., Fiers W., et al. Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int J Cancer 44 (1989) 918-925
63. Kobayashi H., Yagyu T., Kondo T., et al. Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor κB activation and subsequently suppressed ovarian cancer dissemination. Cancer Res 65 (2005) 10464-10471
64. Oliff A., Defeo-Jones D., Boyer M., et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50 (1987) 555-563
65. Cahlin C., Korner A., Axelsson H., et al. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res 60 (2000) 5488-5493
66. Yoneda T., Alsina M.A., Chavez J.B., et al. Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice. J Clin Invest 87 (1991) 977-985
67. Lu T., Burdelya L.G., Swiatkowski S.M., et al. Secreted transforming growth factor beta2 activates NF-κB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci USA 101 (2004) 7112-7117
68. Lu T., Sathe S.S., Swiatkowski S.M., Hampole C.V., and Stark G.R. Secretion of cytokines and growth factors as a general cause of constitutive NFκB activation in cancer. Oncogene 23 (2004) 2138-2145
69. Greten F.R., Eckmann L., Greten T.F., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
70. Pikarsky E., Porat R.M., Stein I., et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
71. Dajee M., Lazarov M., Zhang J.Y., et al. NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421 (2003) 639-643
72. van Hogerlinden M., Auer G., and Toftgard R. Inhibition of Rel/Nuclear Factor-κB signaling in skin results in defective DNA damage-induced cell cycle arrest and Ha-ras- and p53-independent tumor development. Oncogene 21 (2002) 4969-4977